المؤلفون: Méndez-Vidal MJ; Oncology Department, Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofia Hospital, Córdoba, Spain., Molina Á; Oncology Department, Complejo Hospitalario Universitario A Coruña, ACoruña, Spain., Anido U; Oncology Department, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain., Chirivella I; Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain., Etxaniz O; Oncology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain., Fernández-Parra E; Oncology Department, Hospital Nuestra Señora del Valme, Sevilla, Spain., Guix M; Oncology Department, Hospital del Mar, Barcelona, Spain., Hernández C; Medical Oncology Department, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain., Lambea J; Medical Oncology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain., Montesa Á; Medical Oncology Department, Hospital Regional de Málaga, Málaga, Spain., Pinto Á; Medical Oncology Department, Hospital la Paz, Madrid, Spain., Ros S; Oncology Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain., Gallardo E; Oncology Department, Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí I3PT. Universitat Autònoma de Barcelona, Sabadell, Barcelona, Spain. egallardo@tauli.cat.

المصدر: BMC pharmacology & toxicology [BMC Pharmacol Toxicol] 2018 Nov 26; Vol. 19 (1), pp. 77. Date of Electronic Publication: 2018 Nov 26.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Systematic Review

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101590449 Publication Model: Electronic Cited Medium: Internet ISSN: 2050-6511 (Electronic) Linking ISSN: 20506511 NLM ISO Abbreviation: BMC Pharmacol Toxicol

مواضيع طبية MeSH: Angiogenesis Inhibitors/*therapeutic use , Carcinoma, Renal Cell/*drug therapy , Kidney Neoplasms/*drug therapy , Pyrimidines/*therapeutic use , Sulfonamides/*therapeutic use, Angiogenesis Inhibitors/pharmacokinetics ; Carcinoma, Renal Cell/metabolism ; Humans ; Indazoles ; Kidney Neoplasms/metabolism ; Pyrimidines/pharmacokinetics ; Quality of Life ; Sulfonamides/pharmacokinetics ; Treatment Outcome